| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -7,400 | -9,810 | -8,240 | -10,150 | -8,670 |
| Net Income Growth | +24.57% | -19.05% | +18.82% | -17.07% | -8.51% |
Graybug Vision Inc (GRAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Graybug Vision Inc. is a clinical-stage biopharmaceutical company. It is focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve. The company's product candidate includes GB-102, GB-401 and GB-103 which are in clinical stage. Graybug Vision Inc. is headquartered in Redwood City, California.